A great read, thanks Gan_Gans...here is just one extract:
"The present invention is based on the surprising finding that treatment with PPS showed a decrease in BMEL volume and, in some cases, complete reduction in BMELs in a patient with no post-treatment adverse events reported on follow-up. Therefore, PPS may be an improved alternative pharmaceutical option to NSAIDs and corticosteroids with potential disease modifying activity."
" The finding implicates the potential effectiveness of PPS as a treatment option for BMELs and joint effusion in patients and for MCs in patients"
In some cases a complete reduction in BMEL's was a pretty stunning read! I know PAR have stated that we reduce BMEL's...but totally eradicating them? I guess there is an extra chance of this if caught early etc.
Note: MC's means Modic changes. Modic changes means pathological changes to the structure of the spine due to degradation of the spine. 1
The stuff in that publication in regards to potential action on the spine is also quite extraordinary.
This was the clinical results achieved in that report: (I haven't seen this detail before)Table 1. Clinical outcomes
Table 1 Legend
Numerical Rating Scale (NRS) [33] is an 11-point scale (0-10). A state of no pain is 0 and the worst pain imaginable is 10.
Lysholm Knee Score [34] is a total score of 0-100 is calculated based on the results from the eight functional components of the Lysholm knee score scale: Limp (5 points), Support (5 points), Locking (15 points), Instability (25 points), Pain (25 points), Swelling (10 points), Stair climbing (10 points), and Squatting (5 points). The total score is assigned to rating categories as follows: 95-100 indicates excellent, 84-94 indicates good, 65-83 indicates fair and <65 indicates poor function.
---------------------------------------------------------------------------------------
And at what cost? Well as we know already but always good to see and hear it again:
"In conclusion, no adverse events were reported with the use of PPS under the TGA SAS(B) in patients with Bone Marrow Edema Lesions and suffering from osteoarthritis."
References
1) https://www.raynersmale.com/blog/2015/8/21/modic-changes
- Forums
- ASX - By Stock
- PAR
- Application
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
7.53%
!
43.0¢

Application, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
43.0¢ |
Change
-0.035(7.53%) |
Mkt cap ! $170.8M |
Open | High | Low | Value | Volume |
47.0¢ | 47.5¢ | 42.0¢ | $676.1K | 1.519M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16161 | 43.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
44.5¢ | 19584 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 0.430 |
1 | 6684 | 0.425 |
1 | 92843 | 0.420 |
1 | 6531 | 0.415 |
1 | 15000 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.445 | 19584 | 1 |
0.450 | 15000 | 1 |
0.465 | 102000 | 2 |
0.470 | 144093 | 3 |
0.475 | 51156 | 4 |
Last trade - 16.10pm 07/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online